No black box warning on record for Rybrevant

As of the latest FDA labeling reviewed, Rybrevant (AMIVANTAMAB-VMJW) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rybrevant medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Related Reactions (IRR) : Interrupt infusion at the first sign of IRRs. Reduce the infusion rate or permanently discontinue RYBREVANT based on severity. ( 2.5 , 2.8 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of ILD. Immediately withhold RYBREVANT in patients with suspected ILD/pneumonitis and permanentl

No black box warning on record for Rybrevant

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Related Reactions (IRR) : Interrupt infusion at the first sign of IRRs. Reduce the infusion rate or permanently discontinue RYBREVANT based on severity. ( 2.5 , 2.8 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of ILD. Immediately withhold RYBREVANT in patients with suspected ILD/pneumonitis and permanentl

Rybrevant Black Box Warning

No black box warning on record for Rybrevant

Other warnings & precautions

Rybrevant Black Box Warning

No black box warning on record for Rybrevant

Other warnings & precautions